NASDAQ:SYRS Syros Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Syros Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.17 +0.20 (+2.23 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$8.90Now: $9.17▼$9.4850-Day Range$8.69MA: $11.55▼$14.4752-Week Range$4.26Now: $9.17▼$14.69Volume301,184 shsAverage Volume330,831 shsMarket Capitalization$419.64 millionP/E RatioN/ADividend YieldN/ABeta1.72 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. It has target discovery, research collaboration, and option agreement with Incyte to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co., Ltd. for the development and commercialization of SY-1425. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingSyros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, Syros Pharmaceuticals has a forecasted upside of 63.6% from its current price of $9.17.Amount of Analyst CoverageSyros Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesSyros Pharmaceuticals has received 337 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSyros Pharmaceuticals has received 308 “underperform” votes. (Add your “underperform” vote.)Community SentimentSyros Pharmaceuticals has received 52.25% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote “Outperform” if you believe SYRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSyros Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyros Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syros Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $293,696.00 in company stock.Percentage Held by InsidersOnly 14.20% of the stock of Syros Pharmaceuticals is held by insiders.Percentage Held by Institutions97.66% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Syros Pharmaceuticals are expected to decrease in the coming year, from ($1.52) to ($1.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syros Pharmaceuticals is -5.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syros Pharmaceuticals is -5.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyros Pharmaceuticals has a P/B Ratio of 4.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.39 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYRS Previous Symbol CUSIPN/A CIK1556263 Webwww.syros.com Phone617-744-1340Debt Debt-to-Equity Ratio0.73 Current Ratio4.85 Quick Ratio4.85Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.98 million Price / Sales211.94 Cash FlowN/A Price / Cash FlowN/A Book Value$1.87 per share Price / Book4.90Profitability EPS (Most Recent Fiscal Year)($1.88) Net Income$-75,440,000.00 Net Margins-1,114.79% Return on Equity-94.59% Return on Assets-49.05%Miscellaneous Employees76 Outstanding Shares45,762,000Market Cap$419.64 million Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $9.17 +0.20 (+2.23 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive SYRS News and Ratings via Email Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions How has Syros Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SYRS stock has increased by 78.1% and is now trading at $9.17. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Syros Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Syros Pharmaceuticals. When is Syros Pharmaceuticals' next earnings date? Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Syros Pharmaceuticals. How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals Inc (NASDAQ:SYRS) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. The firm earned $3.19 million during the quarter, compared to the consensus estimate of $2.19 million. Syros Pharmaceuticals had a negative net margin of 1,114.79% and a negative return on equity of 94.59%. View Syros Pharmaceuticals' earnings history. What price target have analysts set for SYRS? 7 brokerages have issued 1-year price targets for Syros Pharmaceuticals' shares. Their forecasts range from $9.00 to $20.00. On average, they expect Syros Pharmaceuticals' stock price to reach $15.00 in the next year. This suggests a possible upside of 63.6% from the stock's current price. View analysts' price targets for Syros Pharmaceuticals. Are investors shorting Syros Pharmaceuticals? Syros Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 3,620,000 shares, an increase of 31.2% from the August 15th total of 2,760,000 shares. Based on an average trading volume of 366,600 shares, the days-to-cover ratio is presently 9.9 days. Currently, 9.1% of the company's shares are short sold. View Syros Pharmaceuticals' Short Interest. Who are some of Syros Pharmaceuticals' key competitors? Some companies that are related to Syros Pharmaceuticals include Uniqure (QURE), Cytokinetics (CYTK), Ligand Pharmaceuticals (LGND), Ironwood Pharmaceuticals (IRWD), Y-mAbs Therapeutics (YMAB), Amarin (AMRN), ALX Oncology (ALXO), ZEALAND PHARMA/S (ZEAL), Generation Bio (GBIO), Dicerna Pharmaceuticals (DRNA), MacroGenics (MGNX), Trillium Therapeutics (TRIL), Intercept Pharmaceuticals (ICPT), Mersana Therapeutics (MRSN) and Heron Therapeutics (HRTX). View all competitors. What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Amicus Therapeutics (FOLD), ImmunoGen (IMGN), Amarin (AMRN), Immunomedics (IMMU), Nektar Therapeutics (NKTR) and Intellia Therapeutics (NTLA). Who are Syros Pharmaceuticals' key executives? Syros Pharmaceuticals' management team includes the following people: Dr. Nancy A. Simonian, Pres, CEO & Director (Age 58)Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 65)Dr. David A. Roth, Chief Medical Officer (Age 56)Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 57)Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board When did Syros Pharmaceuticals IPO? (SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Syros Pharmaceuticals' stock symbol? Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS." Who are Syros Pharmaceuticals' major shareholders? Syros Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (14.47%), Sumitomo Mitsui Trust Holdings Inc. (10.34%), Vanguard Group Inc. (4.15%), Point72 Asset Management L.P. (3.35%), Portolan Capital Management LLC (1.09%) and Artal Group S.A. (1.07%). Company insiders that own Syros Pharmaceuticals stock include Eric R Olson, Jeremy P Springhorn, Mark J Alles, Richard A Young, Srinivas Akkaraju and Venture Fund Vii LP Arch. View institutional ownership trends for Syros Pharmaceuticals. Which major investors are selling Syros Pharmaceuticals stock? SYRS stock was sold by a variety of institutional investors in the last quarter, including Arch Venture Corp, Point72 Asset Management L.P., Sumitomo Mitsui Trust Holdings Inc., Artal Group S.A., Portolan Capital Management LLC, State of Wisconsin Investment Board, UBS Group AG, and Bank of America Corp DE. Company insiders that have sold Syros Pharmaceuticals company stock in the last year include Eric R Olson, Richard A Young, and Srinivas Akkaraju. View insider buying and selling activity for Syros Pharmaceuticals. Which major investors are buying Syros Pharmaceuticals stock? SYRS stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., Two Sigma Advisers LP, Nuveen Asset Management LLC, Alps Advisors Inc., California Public Employees Retirement System, Bessemer Group Inc., and Charles Schwab Investment Management Inc.. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn, Mark J Alles, and Srinivas Akkaraju. View insider buying and selling activity for Syros Pharmaceuticals. How do I buy shares of Syros Pharmaceuticals? Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Syros Pharmaceuticals' stock price today? One share of SYRS stock can currently be purchased for approximately $9.17. How big of a company is Syros Pharmaceuticals? Syros Pharmaceuticals has a market capitalization of $419.64 million and generates $1.98 million in revenue each year. The company earns $-75,440,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe. What is Syros Pharmaceuticals' official website? The official website for Syros Pharmaceuticals is www.syros.com. How can I contact Syros Pharmaceuticals? Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected] This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
